Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360640 | 0.81 | CA2 (0.48) | ALDH1A1CYP1A2CYP2C19MAPTMAPK1 | |
| SCHEMBL168783 | 0.81 | CA2 (0.48) | ALDH1A1CYP1A2CYP2C19MAPTMAPK1 | |
| SCHEMBL16962038 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TUBB1HPGDCYP1A2CYP2D6 | |
| SCHEMBL708391 | 0.80 | AR (0.51) | ALDH1A1TUBB1HPGDCYP1A2CYP2D6 | |
| SCHEMBL8078442 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TUBB1HPGDCYP1A2CYP2D6 | |
| SCHEMBL28102237 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TUBB1HPGDCYP1A2CYP2D6 | |
| SCHEMBL30118209 | 0.80 | AR (0.51) | ALDH1A1TUBB1HPGDCYP1A2CYP2D6 | |
| SCHEMBL4304416 | 0.78 | AR (0.40) | ALDH1A1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL21880260 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL23143170 | 0.77 | HPGD (0.50) | ALDH1A1TUBB1HPGDCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606025-B1 | PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF | BASF SE (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-9073844-B2 | Process for preparing a propiolic acid or a derivative thereof | BASF SE (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20140012000-A1 | PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF | BASF SE (DE) | 2014-01-09 | — | — | US | disclosed |
| EP-2606025-A1 | PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF | BASF SE (DE) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022801-A1 | PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF | TECHNISCHE UNIVERSITÄT KAISERSLAUTERN (DE) | 2012-02-23 | — | — | WO | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012000-A1 | PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF | PCCA, C9, AOC3 | ALDH1A1 130/4885TUBB1 3449/4885HPGD 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.